INMED PHARMACEUTICALS INC. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
INMED PHARMACEUTICALS INC. (INM) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $68.31 thousand as of 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-09-09
- 2020-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount 939.13K CAD.
- 2020-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount 198.72K CAD.
CAD
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2020-12-31 | 939.13K CAD 10-Q · filed 2021-02-11 |
| 2020-09-30 | 198.72K CAD 10-Q · filed 2020-12-17 |
USD
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount |
|---|---|
| 2026-06-30 | $68.31K S-4/A · filed 2026-09-09 |
| 2023-12-31 | $187.63K 10-Q · filed 2024-02-13 |
| 2023-09-30 | $42.30K 10-Q · filed 2023-11-14 |
| 2023-06-30 | $51.58K 10-K · filed 2023-09-29 |
| 2023-03-31 | $101.42K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $160.55K 10-Q · filed 2023-02-17 |
| 2022-09-30 | $154.24K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $292.96K 10-K · filed 2022-09-23 |
| 2022-03-31 | $431.56K 10-Q · filed 2022-05-13 |
| 2021-12-31 | $618.62K 10-Q · filed 2022-02-14 |
| 2021-09-30 | $247.52K 10-Q · filed 2021-11-10 |
| 2021-06-30 | $371.78K 10-K · filed 2021-09-24 |
| 2021-03-31 | $527.12K 10-Q · filed 2021-05-13 |
| 2020-12-31 | $737.62K 10-Q · filed 2021-02-11 |
| 2020-09-30 | $148.98K 10-Q · filed 2020-12-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |